CD274 and non-small cell lung carcinoma: In addition, it has been shown that a secreted PD-L1 splicing variant, which lacks a transmembrane structural domain, competitively binds anti-PD-L1 monoclonal antibodies, neutralizing their effects and leading to drug resistance in NSCLC (196).